HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Illumigen Biosciences Inc.

Division of Merck & Co. Inc.

Latest From Illumigen Biosciences Inc.

Pacific Horizon: Encouraging Mutations in the Venture Model

Pacific Horizon is an active venture investor, often owning large majority stakes in its portfolio companies. The venture capitalist has taken two different strategies with its majority-owned virology investments, Illumigen and Koronis, eschewing and embracing risk, respectively. Each firm, however, represents a potential game-changing opportunity, and illustrates PHV's back-to-basics venture philosophy: making novel-mechanism bets that are perceived as having both high scientific risks and long-term potential paybacks
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
      • Molecular Diversity
    • Large Molecule
    • Pharmacogenetics-Pharmacogenomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Merck & Co. Inc.
  • Senior Management
  • Charles L Magness, PhD, Pres. & COO
    Christina Scherer, PhD, Dir., Rsch.
    Shawn P Iadonato, PhD, CSO
  • Contact Info
  • Illumigen Biosciences Inc.
    Phone: (206) 378-0400
    201 Elliot Ave. West, Ste. 500
    Seattle, WA 98119